- Home
- CUBI vs PTGX Comparison
CUBI vs PTGX Comparison
Compare CUBI & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUBI
- PTGX
- Stock Information
- Founded
- CUBI 1994
- PTGX 2006
- Country
- CUBI United States
- PTGX United States
- Employees
- CUBI N/A
- PTGX N/A
- Industry
- CUBI Major Banks
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- CUBI Finance
- PTGX Health Care
- Exchange
- CUBI Nasdaq
- PTGX Nasdaq
- Market Cap
- CUBI 1.4B
- PTGX 2.8B
- IPO Year
- CUBI 2012
- PTGX 2016
- Fundamental
- Price
- CUBI $46.46
- PTGX $47.91
- Analyst Decision
- CUBI Buy
- PTGX Strong Buy
- Analyst Count
- CUBI 8
- PTGX 7
- Target Price
- CUBI $63.86
- PTGX $52.83
- AVG Volume (30 Days)
- CUBI 290.2K
- PTGX 450.1K
- Earning Date
- CUBI 10-31-2024
- PTGX 11-08-2024
- Dividend Yield
- CUBI N/A
- PTGX N/A
- EPS Growth
- CUBI 33.08
- PTGX N/A
- EPS
- CUBI 7.41
- PTGX 2.75
- Revenue
- CUBI $722,462,000.00
- PTGX $319,120,000.00
- Revenue This Year
- CUBI N/A
- PTGX $400.33
- Revenue Next Year
- CUBI $11.71
- PTGX N/A
- P/E Ratio
- CUBI $6.12
- PTGX $17.54
- Revenue Growth
- CUBI 25.87
- PTGX 125.73
- 52 Week Low
- CUBI $38.69
- PTGX $13.76
- 52 Week High
- CUBI $68.49
- PTGX $48.89
- Technical
- Relative Strength Index (RSI)
- CUBI 48.18
- PTGX 60.40
- Support Level
- CUBI $44.31
- PTGX $45.33
- Resistance Level
- CUBI $47.11
- PTGX $48.89
- Average True Range (ATR)
- CUBI 1.57
- PTGX 1.28
- MACD
- CUBI 0.05
- PTGX 0.11
- Stochastic Oscillator
- CUBI 28.96
- PTGX 77.11
About CUBI Customers Bancorp Inc
Customers Bancorp Inc is a bank holding company engaged in banking activities. It provides financial products and services to small and middle-market businesses, not-for-profits, and consumers. The company operates in Lending Activities, Commercial Lending, Consumer Lending, Private Banking, Deposit Products, Other Funding Sources, and Financial Products and Services. The majority of revenue is derived from commercial lending.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.